1.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: ABC-03 09/0193, NCT00939848
|
|
2.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: SWOG-S0905, S0905, NCT01064648
|
|
3.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: DFCI 09-293, U01CA062490-16S2, NCI 8348, NCT01116648
|
|
4.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: UCCRC-10-182-B, 10-182-B, 8317, NCT01208051
|
|
5.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: MGH-06-264, MGH-06-264, 7309, NCT00458978
|
|
6.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00129, MC048H, CDR0000544833, N01CM17104, MCCRC-MC048H, 7135, NCT00475150
|
|
7.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Diagnostic, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2011-02012, U10CA021661, CDR0000665163, RTOG 0837, RTOG-0837-ACRIN-6689, NCT01062425
|
|
8.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 090192, 09-C-0192, NCT00942877
|
|
9.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: GOG-0229J, GOG-0229J, NCT01132820
|
|
10.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CASE9209, U01CA062502, NCI-2011-02535, CWRU-CASE-9209, 8323, NCT01229111
|
|
11.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Over 18 Sponsor: Other, Pharmaceutical / Industry Protocol IDs: CRUK-C-2009-01, CRUK CIRCCa, CIRCCa, EUDRACT-2009-011542-25, ISRCTN-23516549, EU-21080, ZENECA-CRUK-C-2009-01, NCT01229930
|
|
12.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: CRUK-UCL-10/0035, UCL/10/0035 v1.0, DORIC, ZENECA-ISSRECE00002, EUDRACT-2010-021531-13, CRUKE/10/044, NCT01310855
|
|
13.
|
Phase: Phase II Type: Treatment Status: Active Age: 16 and over Sponsor: Other Protocol IDs: ICR-CTSU/2010/10027, 2010-021163-33, CRUK/10/021, ISRCTN63733470, ISSRECE0036, NCT01337401
|
|
14.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 16 to 20 Sponsor: NCI Protocol IDs: 110200, 11-C-0200, NCT01391962
|
|
15.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: ABTC-0903 CDR0000654715, U01CA137443, ABTC-0903, 0903, NCT00979862
|
|
16.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 09_DOG03_184, 2009-016524-31, NCT01160926
|
|
17.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 years and over Sponsor: NCI Protocol IDs: MAYO-MC1012, MC1012, 8810, NCT01364051
|